The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Enhanced T-cell fitness in high-risk smoldering vs R/R myeloma with bispecifics and CAR-T
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses single-cell immune profiling showing superior immune fitness of both endogenous and engineered T-cells in patients with high-risk smoldering myeloma compared with those treated in the relapsed/refractory (R/R) setting. She explains the potential benefit of earlier use of bispecific antibodies and CAR T-cell therapies by leveraging a more intact immune system. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
